AR and prostate neoplasm: Consequently, our data suggests that YIV-818-A, RA-V, and RA-VII may possess potential to target prostate tumors bearing either wild type AR or AR-V (AR splice variants), thereby promising to substantially attenuate, if not completely nullify, the drug resistance manifested in 22RV1 cells.